Feniman De Stefano 2015.

Study characteristics
Methods	Study design: parallel RCT Study duration: March 2011 to December 2012 Follow‐up period: 24 weeks
Participants	Setting: single centre Country: Brazil Relevant health status: CKD‐5D on HD; stable antihypertensive treatment in the last 6 months Number (randomised/analysed): treatment group (10/8); control group (9/9) Mean age ± SD (years): treatment group (52.0 ± 19.2); control group (56.0 ± 10.9) Sex (M/F): treatment group (4/4); control group (5/4) Exclusion criteria: dialysis dose measured by Kt/V < 1.2; history or evidence of angina or MI, heart failure, peripheral vascular disease, previous hyperkalaemia, valvular heart disease, atrial fibrillation; Hb < 10 g/dL; patients under treatment with spironolactone
Interventions	Treatment group Spironolactone: 25 mg/day for 24 weeks Control group Placebo for 24 weeks
Outcomes	LVM EF Serum potassium
Identification	Authors name: Greicy Mara Mengue Feniman‐De‐Stefano Institution: Dpto de Clínica Médica da Faculdad Email: gmmfds@yahoo.com.br Address: UNESP, 440 Rua João Miguel Rafael, Botucatu, CEP 18602‐220, São Paulo, Brazil
Notes	Funding source: Funded by FUNDUNESP (Foundation for the Development of UNESP, Process 0090910) and FAPESP (Foundation for Research Support of São Paulo, Process 2010/10439‐1) Complete follow‐up: treatment group (8/10, 80%); control group (9/9, 100%)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how sequence generation was done
Allocation concealment (selection bias)	Unclear risk	Only states the study was randomised, does not ensure how allocation concealment was done
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "double‐blind", "placebo‐controlled"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "double‐blind", "placebo‐controlled"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced across intervention groups
Selective reporting (reporting bias)	Low risk	All prespecified outcomes have been reported in ClinicalTrials.gov identifier NCT01128101
Other bias	Low risk	Funded by FUNDUNESP (Foundation for the Development of UNESP, Process 0090910) and FAPESP (Foundation for Research Support of São Paulo, Process 2010/10439‐1)